KLRK1 and inflammatory bowel disease: In human IBD, the expression and function of NKG2D have not been fully characterized [12], but a recent phase II clinical trial showed that a blocking antibody against NKG2D induced rapid clinical remission of CD in some patients, implicating NKG2D and its ligands to be of importance in the pathogenesis of CD [13].